What is Bristol Myers's earnings per share (EPS)?

Bristol Myers (BMYMP) reported diluted earnings per share of $3.46 for fiscal year 2025. This represents a 178.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bristol Myers (BMYMP) Financials

BMYMP

Trailing 12 months to March 31, 2026

Revenue $48.5B +1.8% YoY

Net Income $7.3B +34.2% YoY

EPS (Diluted) $3.46 FY2025 annual

Free Cash Flow $11.9B -9.0% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Apr 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed Apr 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BMYMP SEC filings page.

Bristol Myers (BMYMP) reported $48.5B in revenue over the twelve months to Mar 31, 2026, up 1.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BMYMP FY2025 2026-08-30

The dominant mechanic is resilient cash generation alongside thinner gross margins and a balance sheet reshaped by FY2024’s earnings shock.

In FY2024, the company produced operating cash flow of $15.2B despite a net loss of -$8.9B, so the reported loss did not represent an equivalent cash drain; the reversal to $7.1B profit in FY2025 restored accounting earnings without lifting gross margin above 71.1%. That pairing points to a cash engine steadier than bottom-line results, while profitability remains exposed to cost or mix pressure.

Revenue was essentially flat at $48.2B in FY2025 versus $48.3B in FY2024, so sales volume does not explain the weaker margin structure. Gross margin was 71.1% in FY2025 versus 78.6% in FY2021, pointing to cost or mix changes rather than demand-led deterioration.

The balance sheet carries more leverage than before: debt-to-equity was 2.3x in FY2025 versus 1.1x in FY2021, while equity fell to $18.5B from $35.9B. Yet a 1.3x current ratio and operating cash flow of $14.2B indicate short-term obligations are being supported by ongoing operations, not just asset sales.

Financial Health Signals

Financial health score not available

Bristol Myers does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Strong

7/9

Bristol Myers passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

2.01x

For every $1 of reported earnings, Bristol Myers generates $2.01 in operating cash flow ($14.2B OCF vs $7.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$11.5B

YoY+2.6%

QoQ-8.1%

5Y CAGR+0.7%

10Y CAGR+10.1%

Bristol Myers generated $11.5B in revenue in Q1 2026. This represents an increase of 2.6% from the same quarter a year earlier. Against the prior quarter it is down 8.1%.

Net Income

$2.7B

YoY+9.0%

QoQ+146.3%

5Y CAGR+5.8%

10Y CAGR+8.4%

Bristol Myers reported $2.7B in net income in Q1 2026. This represents an increase of 9.0% from the same quarter a year earlier. Against the prior quarter it is up 146.3%.

EPS (Diluted)

$1.31

YoY+9.2%

Bristol Myers earned $1.31 per diluted share (EPS) in Q1 2026. This represents an increase of 9.2% from the same quarter a year earlier.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Free Cash Flow

$757.0M

YoY-55.3%

QoQ-52.8%

5Y CAGR-27.0%

Bristol Myers generated $757.0M in free cash flow in Q1 2026, representing cash available after capex. This represents a decrease of 55.3% from the same quarter a year earlier. Against the prior quarter it is down 52.8%.

Cash & Debt

$9.6B

YoY-12.0%

QoQ-6.2%

5Y CAGR-2.7%

10Y CAGR+13.7%

Bristol Myers held $9.6B in cash against $42.2B in long-term debt as of Q1 2026.

Dividends Per Share

$0.63

YoY+1.6%

Bristol Myers paid $0.63 per share in dividends in Q1 2026. This represents an increase of 1.6% from the same quarter a year earlier.

Shares Outstanding

2.04B

YoY+0.3%

QoQ+0.3%

5Y CAGR-1.8%

10Y CAGR+2.0%

Bristol Myers had 2.04B shares outstanding in Q1 2026. This represents an increase of 0.3% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Margins & Returns

Gross Margin

70.2%

YoY-2.7pp

QoQ+3.0pp

5Y CAGR-4.1pp

10Y CAGR-5.8pp

Bristol Myers's gross margin was 70.2% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.0 percentage points.

Net Margin

23.3%

YoY+1.4pp

QoQ+14.6pp

5Y CAGR+5.1pp

10Y CAGR-3.9pp

Bristol Myers's net profit margin was 23.3% in Q1 2026, showing the share of revenue converted to profit. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 14.6 percentage points.

Return on Equity

13.3%

YoY-0.8pp

QoQ+7.5pp

5Y CAGR+8.0pp

10Y CAGR+5.0pp

Bristol Myers's ROE was 13.3% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.5 percentage points.

Operating Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$2.6B

YoY+17.4%

QoQ+2.4%

5Y CAGR+3.6%

Bristol Myers invested $2.6B in research and development in Q1 2026. This represents an increase of 17.4% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.

Capital Expenditures

$347.0M

YoY+33.5%

QoQ-6.2%

5Y CAGR+14.9%

10Y CAGR+3.7%

Bristol Myers invested $347.0M in capex in Q1 2026, funding long-term assets and infrastructure. This represents an increase of 33.5% from the same quarter a year earlier. Against the prior quarter it is down 6.2%.

Share Buybacks

Not reported for Q1 2026.

BMYMP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BMYMP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$48.5B	$48.2B-0.2%	$48.3B+7.3%	$45.0B-2.5%	$46.2B-0.5%	$46.4B+9.1%	$42.5B+62.6%	$26.1B+15.9%	$22.6B+8.6%	$20.8B+6.9%	$19.4B+17.3%	$16.6B+4.3%	$15.9B-3.1%	$16.4B-7.0%	$17.6B-17.1%	$21.2B
Cost of Revenue	$14.3B	$13.9B-0.2%	$14.0B+30.6%	$10.7B+5.5%	$10.1B+2.0%	$9.9B-15.6%	$11.8B+45.7%	$8.1B+24.9%	$6.5B+7.5%	$6.0B+21.0%	$5.0B+27.1%	$3.9B-0.6%	$3.9B-14.9%	$4.6B+0.2%	$4.6B-17.6%	$5.6B
Gross Profit	$34.2B	$34.3B-0.2%	$34.3B+0.1%	$34.3B-4.7%	$36.0B-1.2%	$36.4B+18.5%	$30.7B+70.2%	$18.1B+12.3%	$16.1B+9.6%	$14.7B+1.4%	$14.5B+14.5%	$12.7B+5.9%	$11.9B+1.5%	$11.8B-9.6%	$13.0B-16.8%	$15.6B
R&D Expenses	$10.3B	$10.0B-10.8%	$11.2B+20.0%	$9.3B-2.2%	$9.5B-6.7%	$10.2B+1.5%	$10.0B+63.4%	$6.1B-2.9%	$6.3B-2.1%	$6.5B+29.1%	$5.0B-15.3%	$5.9B+30.6%	$4.5B+21.5%	$3.7B-4.4%	$3.9B+1.7%	$3.8B
SG&A Expenses	$7.3B	$7.3B-13.6%	$8.4B+8.3%	$7.8B-0.5%	$7.8B+1.6%	$7.7B+0.4%	$7.7B+57.3%	$4.9B+7.0%	$4.6B-4.2%	$4.8B-4.6%	$5.0B+2.9%	$4.8B+0.4%	$4.8B-2.4%	$4.9B+17.0%	$4.2B+0.4%	$4.2B
Interest Expense	$1.8B	$1.9B-2.9%	$1.9B+67.0%	$1.2B-5.4%	$1.2B-7.6%	$1.3B-6.1%	$1.4B+116.5%	$656.0M+258.5%	$183.0M-6.6%	$196.0M+17.4%	$167.0M-9.2%	$184.0M-9.4%	$203.0M+2.0%	$199.0M+9.3%	$182.0M+25.5%	$145.0M
Income Tax	$2.3B	$2.3B+310.1%	$554.0M+38.5%	$400.0M-70.8%	$1.4B+26.2%	$1.1B-49.0%	$2.1B+40.2%	$1.5B+48.4%	$1.0B-75.4%	$4.2B+195.2%	$1.4B+215.7%	$446.0M+26.7%	$352.0M+13.2%	$311.0M+293.2%	-$161.0M-109.4%	$1.7B
Net Income	$7.3B	$7.1B+178.8%	-$8.9B-211.5%	$8.0B+26.8%	$6.3B-9.5%	$7.0B+177.6%	-$9.0B-362.1%	$3.4B-30.1%	$4.9B+388.6%	$1.0B-77.4%	$4.5B+184.8%	$1.6B-21.9%	$2.0B-21.8%	$2.6B+30.8%	$2.0B-47.2%	$3.7B
EPS (Basic)	N/A	$3.47+178.7%	-$4.41-213.7%	$3.88+30.6%	$2.97-5.7%	$3.15+178.9%	-$3.99-297.5%	$2.02-32.9%	$3.01+393.4%	$0.61-77.2%	$2.67+184.0%	$0.94-22.3%	$1.21-22.4%	$1.56+33.3%	$1.17-46.3%	$2.18
EPS (Diluted)	—	$3.46+178.5%	-$4.41-214.2%	$3.86+30.8%	$2.95-5.4%	$3.12+178.2%	-$3.99-298.5%	$2.01-33.2%	$3.01+393.4%	$0.61-77.0%	$2.65+184.9%	$0.93-22.5%	$1.20-22.1%	$1.54+32.8%	$1.16-46.3%	$2.16
Diluted Shares (Avg)	N/A	2.04B+0.6%	2.03B-2.5%	2.08B-3.2%	2.15B-4.4%	2.25B-0.6%	2.26B+31.9%	1.71B+4.6%	1.64B-0.9%	1.65B-1.7%	1.68B+0.1%	1.68B+0.5%	1.67B+0.5%	1.66B-1.5%	1.69B-1.7%	1.72B

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$11.5B+2.6%	$12.5B+1.3%	$12.2B+2.8%	$12.3B+0.6%	$11.2B-5.6%	$12.3B+7.5%	$11.9B+8.4%	$12.2B+8.7%
Cost of Revenue	$3.4B+12.8%	$4.1B-14.9%	$3.4B+16.2%	$3.4B+3.2%	$3.0B+3.4%	$4.8B+75.3%	$3.0B+18.0%	$3.3B+13.6%
Gross Profit	$8.1B-1.2%	$8.4B+11.6%	$8.8B-1.7%	$8.9B-0.4%	$8.2B-8.6%	$7.5B-13.8%	$8.9B+5.6%	$8.9B+7.0%
R&D Expenses	$2.6B+17.4%	$2.6B-19.0%	$2.5B+6.5%	$2.6B-11.0%	$2.3B-16.3%	$3.2B+28.8%	$2.4B+5.9%	$2.9B+28.4%
SG&A Expenses	$1.6B+2.1%	$2.2B+2.1%	$1.8B-9.8%	$1.7B-11.2%	$1.6B-33.1%	$2.1B+3.0%	$2.0B-1.0%	$1.9B-0.3%
Interest Expense	$411.0M-16.8%	$432.0M-12.9%	$480.0M-5.0%	$485.0M-6.9%	$494.0M+16.2%	$496.0M+57.0%	$505.0M+80.4%	$521.0M+84.8%
Income Tax	$561.0M+10.2%	$384.0M+287.9%	$919.0M+99.3%	$460.0M+215.6%	$509.0M+29.8%	$99.0M+212.5%	$461.0M+127.1%	-$398.0M-82.6%
Net Income	$2.7B+9.0%	$1.1B+1409.7%	$2.2B+81.8%	$1.3B-22.0%	$2.5B+120.6%	$72.0M-95.9%	$1.2B-37.2%	$1.7B-19.0%
EPS (Basic)	$1.31+8.3%	N/A	$1.08+80.0%	$0.64-22.9%	$1.21+120.5%	N/A	$0.60-36.2%	$0.83-16.2%
EPS (Diluted)	$1.31+9.2%	N/A	$1.08+80.0%	$0.64-22.9%	$1.20+120.4%	N/A	$0.60-35.5%	$0.83-16.2%
Diluted Shares (Avg)	2.05B+0.3%	N/A	2.04B+0.4%	2.04B+0.4%	2.04B+0.8%	N/A	2.03B-1.6%	2.03B-3.5%

Not reported in any period shown, so not listed: Operating Income, EBITDA.

BMYMP Balance Sheet

BMYMP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$90.0B-2.8%	$92.6B-2.7%	$95.2B-1.7%	$96.8B-11.4%	$109.3B-7.7%	$118.5B-8.8%	$129.9B+271.4%	$35.0B+4.3%	$33.6B-0.5%	$33.7B+6.2%	$31.7B-5.9%	$33.7B-12.5%	$38.6B+7.5%	$35.9B+8.9%	$33.0B
Current Assets	$29.4B-1.3%	$29.8B-6.3%	$31.8B+16.5%	$27.3B-18.0%	$33.3B+10.2%	$30.2B+2.9%	$29.4B+65.7%	$17.7B+19.3%	$14.9B+8.4%	$13.7B+31.6%	$10.4B-28.7%	$14.6B-22.8%	$18.9B+98.7%	$9.5B-37.8%	$15.3B
Cash & Equivalents	$10.2B-1.3%	$10.3B-9.8%	$11.5B+25.7%	$9.1B-34.7%	$14.0B-3.9%	$14.5B+17.8%	$12.3B+78.6%	$6.9B+27.5%	$5.4B+27.9%	$4.2B+77.7%	$2.4B-57.2%	$5.6B+55.4%	$3.6B+116.5%	$1.7B-71.3%	$5.8B
Inventory	$2.7B+5.2%	$2.6B-3.9%	$2.7B+13.8%	$2.3B+11.6%	$2.1B+1.0%	$2.1B-51.7%	$4.3B+259.2%	$1.2B+2.5%	$1.2B-6.0%	$1.2B+1.6%	$1.2B-21.7%	$1.6B+4.1%	$1.5B-9.6%	$1.7B+19.7%	$1.4B
Accounts Receivable	$9.6B+6.4%	$9.0B+1.5%	$8.9B+9.0%	$8.2B+2.2%	$8.0B+10.5%	$7.2B+11.5%	$6.5B+39.7%	$4.6B+6.6%	$4.3B+15.2%	$3.8B+28.0%	$2.9B+40.4%	$2.1B+24.3%	$1.7B-1.1%	$1.7B-24.1%	$2.3B
Goodwill	$21.8B+0.2%	$21.7B+2.6%	$21.2B+0.1%	$21.1B+3.2%	$20.5B-0.2%	$20.5B-8.6%	$22.5B+244.0%	$6.5B-4.7%	$6.9B-0.2%	$6.9B-0.1%	$6.9B-2.1%	$7.0B-1.0%	$7.1B-7.1%	$7.6B+36.7%	$5.6B
Total Liabilities	$71.5B-6.1%	$76.2B+16.1%	$65.7B0.0%	$65.7B-10.4%	$73.3B-9.0%	$80.6B+3.0%	$78.2B+275.1%	$20.9B-3.9%	$21.7B+25.0%	$17.4B+0.2%	$17.3B-7.7%	$18.8B-19.7%	$23.4B+4.9%	$22.3B+30.1%	$17.1B
Current Liabilities	$23.4B-1.5%	$23.8B+6.8%	$22.3B+1.7%	$21.9B+0.1%	$21.9B+14.6%	$19.1B+4.2%	$18.3B+71.8%	$10.7B+11.4%	$9.6B+8.2%	$8.8B+10.3%	$8.0B-5.2%	$8.5B-32.0%	$12.4B+50.3%	$8.3B+6.4%	$7.8B
Non-Current Liabilities	$48.1B-8.2%	$52.4B+20.8%	$43.4B-0.9%	$43.8B-14.8%	$51.4B-16.4%	$61.5B+2.6%	$59.9B+487.4%	$10.2B-15.9%	$12.1B+42.5%	$8.5B-8.5%	$9.3B-9.7%	$10.3B-5.6%	$10.9B-21.9%	$14.0B+50.0%	$9.3B
Long-Term Debt	$42.9B-10.0%	$47.6B+29.9%	$36.7B+4.6%	$35.1B-11.5%	$39.6B-18.1%	$48.3B+11.4%	$43.4B+668.5%	$5.6B-19.1%	$7.0B+22.0%	$5.7B-12.7%	$6.5B-9.6%	$7.2B-9.3%	$8.0B+21.5%	$6.6B+22.2%	$5.4B
Total Equity	$18.5B+13.1%	$16.3B-44.5%	$29.4B-5.3%	$31.1B-13.6%	$35.9B-5.0%	$37.8B-26.7%	$51.6B+267.7%	$14.0B+19.5%	$11.7B-27.4%	$16.2B+13.4%	$14.3B-3.9%	$14.9B-2.0%	$15.2B+11.2%	$13.6B-14.6%	$16.0B
Retained Earnings	$16.9B+13.3%	$14.9B-48.2%	$28.8B+12.8%	$25.5B+7.1%	$23.8B+11.9%	$21.3B-38.3%	$34.5B+1.2%	$34.1B+9.3%	$31.2B-7.0%	$33.5B+6.0%	$31.6B-2.9%	$32.5B-1.2%	$33.0B+0.7%	$32.7B-1.0%	$33.1B

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$86.5B-6.4%	$90.0B-2.8%	$96.9B+3.4%	$94.7B0.0%	$92.4B-6.7%	$92.6B-2.7%	$93.7B+2.6%	$94.6B+1.2%
Current Assets	$27.2B-11.6%	$29.4B-1.3%	$35.6B+26.9%	$33.2B+23.5%	$30.8B+7.4%	$29.8B-6.3%	$28.1B+1.6%	$26.9B-4.2%
Cash & Equivalents	$9.6B-12.0%	$10.2B-1.3%	$15.7B+99.3%	$12.6B+100.2%	$10.9B+16.6%	$10.3B-9.8%	$7.9B+5.0%	$6.3B-24.8%
Inventory	$2.8B+3.4%	$2.7B+5.2%	$2.8B-17.2%	$2.7B-11.0%	$2.7B-10.7%	$2.6B-3.9%	$3.3B+36.8%	$3.1B+30.2%
Accounts Receivable	$7.9B-12.3%	$9.6B+6.4%	$9.6B+3.3%	$9.7B-0.4%	$9.1B+2.7%	$9.0B+1.5%	$9.3B+10.8%	$9.7B+20.0%
Goodwill	$21.7B0.0%	$21.8B+0.2%	$21.7B0.0%	$21.8B+0.2%	$21.7B0.0%	$21.7B+2.6%	$21.8B+2.9%	$21.7B+2.7%
Total Liabilities	$66.4B-11.5%	$71.5B-6.1%	$78.3B+2.4%	$77.2B-0.5%	$75.0B-9.1%	$76.2B+16.1%	$76.5B+22.9%	$77.6B+26.2%
Current Liabilities	$19.2B-20.4%	$23.4B-1.5%	$28.1B+24.3%	$27.5B+18.3%	$24.1B-6.8%	$23.8B+6.8%	$22.6B-3.5%	$23.3B+15.5%
Non-Current Liabilities	$47.2B-7.3%	$48.1B-8.2%	$50.2B-6.8%	$49.7B-8.6%	$50.9B-10.2%	$52.4B+20.8%	$53.8B+39.0%	$54.3B+31.5%
Long-Term Debt	$42.2B-8.7%	$42.9B-10.0%	$44.5B-8.6%	$44.5B-9.0%	$46.2B-6.7%	$47.6B+29.9%	$48.7B+51.5%	$48.9B+41.0%
Total Equity	$20.1B+15.4%	$18.5B+13.1%	$18.6B+8.2%	$17.4B+2.5%	$17.4B+5.5%	$16.3B-44.5%	$17.1B-40.9%	$17.0B-46.8%
Retained Earnings	$18.3B+13.5%	$16.9B+13.3%	$17.1B+6.2%	$16.2B+0.3%	$16.1B+3.0%	$14.9B-48.2%	$16.1B-43.0%	$16.1B-41.3%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.

BMYMP Cash Flow Statement

BMYMP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$13.3B	$14.2B-6.8%	$15.2B+9.6%	$13.9B+6.1%	$13.1B-19.4%	$16.2B+15.3%	$14.1B+71.2%	$8.2B+16.2%	$7.1B+34.0%	$5.3B+72.5%	$3.1B+45.3%	$2.1B-33.1%	$3.1B-11.2%	$3.5B-48.9%	$6.9B+43.4%	$4.8B
Depreciation & Amortization	N/A	$4.0B-58.2%	$9.6B-1.6%	$9.8B-5.0%	$10.3B-3.8%	$10.7B+2.9%	$10.4B+494.5%	$1.7B+174.1%	$637.0M-19.3%	$789.0M+106.5%	$382.0M+1.6%	$376.0M-19.5%	$467.0M-38.8%	$763.0M+12.0%	$681.0M+8.4%	$628.0M
Stock-Based Compensation	N/A	$553.0M+9.1%	$507.0M-2.1%	$518.0M+13.3%	$457.0M-21.6%	$583.0M-25.2%	$779.0M+76.6%	$441.0M+99.5%	$221.0M+11.1%	$199.0M-2.9%	$205.0M-12.8%	$235.0M+10.3%	$213.0M+11.5%	$191.0M+24.0%	$154.0M-4.3%	$161.0M
Capital Expenditures	$1.4B	$1.3B+5.0%	$1.2B+3.2%	$1.2B+8.1%	$1.1B+14.9%	$973.0M+29.2%	$753.0M-9.9%	$836.0M-12.1%	$951.0M-9.9%	$1.1B-13.2%	$1.2B+48.2%	$820.0M+55.9%	$526.0M-2.0%	$537.0M-2.0%	$548.0M+49.3%	$367.0M
Free Cash Flow	$11.9B	$12.8B-7.9%	$13.9B+10.2%	$12.7B+5.9%	$11.9B-21.6%	$15.2B+14.5%	$13.3B+80.3%	$7.4B+20.6%	$6.1B+44.9%	$4.2B+129.0%	$1.8B+43.4%	$1.3B-51.0%	$2.6B-12.8%	$3.0B-52.9%	$6.4B+42.9%	$4.5B
Investing Cash Flow	-$3.8B	-$4.1B+80.6%	-$21.4B-830.4%	-$2.3B-116.1%	-$1.1B-97.4%	-$538.0M+95.0%	-$10.9B-9.5%	-$9.9B-395.7%	-$2.0B-2930.3%	-$66.0M-104.5%	$1.5B+194.1%	-$1.6B-229.3%	$1.2B+312.6%	-$572.0M+91.5%	-$6.7B-368.1%	-$1.4B
Financing Cash Flow	-$10.9B	-$10.3B-301.8%	$5.1B+154.4%	-$9.4B+44.5%	-$17.0B-4.5%	-$16.2B-1309.6%	-$1.2B-115.1%	$7.6B+315.6%	-$3.5B+13.3%	-$4.1B-53.7%	-$2.7B+26.8%	-$3.6B-48.7%	-$2.4B-128.2%	-$1.1B+75.4%	-$4.3B-63.1%	-$2.7B
Dividends Paid	$5.1B	$5.0B+3.7%	$4.9B+2.5%	$4.7B+2.4%	$4.6B+5.4%	$4.4B+7.9%	$4.1B+52.1%	$2.7B+2.5%	$2.6B+1.4%	$2.6B+1.2%	$2.5B+2.8%	$2.5B+3.3%	$2.4B+3.9%	$2.3B+1.0%	$2.3B+1.4%	$2.3B
Share Buybacks	N/A	$0	$0-100.0%	$5.2B-35.6%	$8.0B+27.3%	$6.3B+306.7%	$1.5B-78.8%	$7.3B+2181.3%	$320.0M-87.0%	$2.5B+968.8%	$231.0M	N/A	N/A	$433.0M-82.0%	$2.4B+96.8%	$1.2B

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	$1.1B-43.5%	$2.0B-55.5%	$6.3B+12.9%	$3.9B+68.4%	$2.0B-31.1%	$4.4B+4.4%	$5.6B+17.7%	$2.3B+23.3%
Depreciation & Amortization	$594.0M-41.3%	$944.0M-51.4%	$1.0B-60.0%	$1.0B-59.8%	$1.0B-60.0%	$1.9B-20.1%	$2.6B+4.7%	$2.6B+4.5%
Stock-Based Compensation	$146.0M+1.4%	N/A	$139.0M+7.8%	$138.0M+10.4%	$144.0M+8.3%	N/A	$129.0M-2.3%	$125.0M-8.8%
Capital Expenditures	$347.0M+33.5%	$370.0M-2.1%	$320.0M-1.2%	$361.0M+37.8%	$260.0M-8.5%	$378.0M+14.5%	$324.0M-5.3%	$262.0M+1.2%
Free Cash Flow	$757.0M-55.3%	$1.6B-60.5%	$6.0B+13.7%	$3.6B+72.3%	$1.7B-33.6%	$4.1B+3.5%	$5.3B+19.5%	$2.1B+26.8%
Investing Cash Flow	-$131.0M+73.7%	-$1.5B-643.9%	-$1.7B-677.2%	-$473.0M+64.1%	-$499.0M+97.5%	-$196.0M+85.4%	-$219.0M+46.6%	-$1.3B-300.9%
Financing Cash Flow	-$1.6B-57.1%	-$6.0B-267.2%	-$1.5B+61.3%	-$1.8B+54.4%	-$993.0M-106.8%	-$1.6B-269.8%	-$3.9B+25.3%	-$4.0B-85.1%
Dividends Paid	$1.3B+2.0%	$1.3B+3.6%	$1.3B+3.9%	$1.3B+3.7%	$1.3B+3.8%	$1.2B+5.0%	$1.2B+2.1%	$1.2B+1.7%
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$0-100.0%

BMYMP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BMYMP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	71.1%0.0pp	71.1%-5.2pp	76.2%-1.8pp	78.0%-0.5pp	78.6%+6.3pp	72.3%+3.2pp	69.1%-2.2pp	71.3%+0.7pp	70.7%-3.9pp	74.5%-1.9pp	76.4%+1.2pp	75.2%+3.4pp	71.8%-2.0pp	73.8%+0.2pp	73.7%
Net Margin	14.6%+33.2pp	-18.5%-36.4pp	17.8%+4.1pp	13.7%-1.4pp	15.1%+36.3pp	-21.2%-34.4pp	13.2%-8.7pp	21.8%+17.0pp	4.9%-18.1pp	22.9%+13.5pp	9.4%-3.2pp	12.6%-3.0pp	15.6%+4.5pp	11.1%-6.3pp	17.5%
Return on Equity	38.2%+93.0pp	-54.8%-82.0pp	27.3%+6.9pp	20.4%+0.9pp	19.5%+43.3pp	-23.8%-30.5pp	6.7%-28.4pp	35.1%+26.5pp	8.6%-19.0pp	27.6%+16.6pp	11.0%-2.5pp	13.5%-3.4pp	16.9%+2.5pp	14.4%-8.9pp	23.3%
Return on Assets	7.8%+17.5pp	-9.7%-18.1pp	8.4%+1.9pp	6.5%+0.1pp	6.4%+14.0pp	-7.6%-10.3pp	2.6%-11.4pp	14.1%+11.1pp	3.0%-10.2pp	13.2%+8.3pp	4.9%-1.0pp	5.9%-0.7pp	6.6%+1.2pp	5.5%-5.8pp	11.3%
Current Ratio	1.260.0x	1.25-0.2x	1.43+0.2x	1.25-0.3x	1.52-0.1x	1.580.0x	1.60-0.1x	1.66+0.1x	1.550.0x	1.55+0.3x	1.30-0.4x	1.73+0.2x	1.52+0.4x	1.15-0.8x	1.97
Debt-to-Equity	2.32-0.6x	2.91+1.7x	1.25+0.1x	1.130.0x	1.10-0.2x	1.28+0.4x	0.84+0.4x	0.40-0.2x	0.59+0.2x	0.35-0.1x	0.460.0x	0.490.0x	0.530.0x	0.48+0.1x	0.34
Asset Turnover	0.540.0x	0.520.0x	0.470.0x	0.48+0.1x	0.42+0.1x	0.36+0.2x	0.20-0.4x	0.640.0x	0.620.0x	0.58+0.1x	0.52+0.1x	0.470.0x	0.42-0.1x	0.49-0.2x	0.64
FCF Margin	26.7%-2.2pp	28.9%+0.8pp	28.1%+2.2pp	25.9%-7.0pp	32.8%+1.6pp	31.3%+3.1pp	28.2%+1.1pp	27.1%+6.8pp	20.3%+10.8pp	9.5%+1.7pp	7.8%-8.8pp	16.5%-1.9pp	18.4%-17.9pp	36.3%+15.2pp	21.1%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Gross Margin	70.2%-2.7pp	67.2%+6.2pp	71.9%-3.2pp	72.5%-0.7pp	72.9%-2.4pp	61.0%-15.1pp	75.1%-2.0pp	73.2%-1.2pp
Net Margin	23.3%+1.4pp	8.7%+8.1pp	18.0%+7.8pp	10.7%-3.1pp	21.9%	0.6%-14.8pp	10.2%-7.4pp	13.8%-4.7pp
Return on Equity	13.3%-0.8pp	5.9%+5.4pp	11.9%+4.8pp	7.5%-2.4pp	14.1%+86.4pp	0.4%-5.5pp	7.1%+0.4pp	9.9%+3.4pp
Return on Assets	3.1%+0.4pp	1.2%+1.1pp	2.3%+1.0pp	1.4%-0.4pp	2.7%+14.7pp	0.1%-1.8pp	1.3%-0.8pp	1.8%-0.4pp
Current Ratio	1.42+0.1x	1.260.0x	1.270.0x	1.21+0.1x	1.28+0.2x	1.25-0.2x	1.24+0.1x	1.16-0.2x
Debt-to-Equity	2.10-0.6x	2.32-0.6x	2.40-0.4x	2.55-0.3x	2.65-0.3x	2.91+1.7x	2.84+1.7x	2.87+1.8x
Asset Turnover	0.130.0x	0.140.0x	0.130.0x	0.130.0x	0.120.0x	0.130.0x	0.130.0x	0.130.0x
FCF Margin	6.6%-8.5pp	12.8%-20.1pp	49.0%+4.7pp	29.0%+12.1pp	15.1%-6.4pp	32.9%-1.3pp	44.3%+4.1pp	16.9%+2.4pp

Not reported in any period shown, so not listed: Operating Margin.

Where Bristol Myers Ranks

Frequently Asked Questions

What is Bristol Myers's annual revenue?

Bristol Myers (BMYMP) reported $48.2B in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bristol Myers's revenue growing?

Bristol Myers (BMYMP) revenue declined by 0.2% year-over-year, from $48.3B to $48.2B in fiscal year 2025.

Is Bristol Myers profitable?

Yes, Bristol Myers (BMYMP) reported a net income of $7.1B in fiscal year 2025, with a net profit margin of 14.6%.

How much debt does Bristol Myers have?

As of fiscal year 2025, Bristol Myers (BMYMP) had $10.2B in cash and equivalents against $42.9B in long-term debt.

What is Bristol Myers's gross margin?

Bristol Myers (BMYMP) had a gross margin of 71.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bristol Myers's net profit margin?

Bristol Myers (BMYMP) had a net profit margin of 14.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Bristol Myers pay dividends?

Yes, Bristol Myers (BMYMP) paid $2.49 per share in dividends during fiscal year 2025.

What is Bristol Myers's return on equity (ROE)?

Bristol Myers (BMYMP) has a return on equity of 38.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bristol Myers's free cash flow?

Bristol Myers (BMYMP) generated $12.8B in free cash flow during fiscal year 2025. This represents a -7.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bristol Myers's operating cash flow?

Bristol Myers (BMYMP) generated $14.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bristol Myers's total assets?

Bristol Myers (BMYMP) had $90.0B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bristol Myers's capital expenditures?

Bristol Myers (BMYMP) invested $1.3B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bristol Myers spend on research and development?

Bristol Myers (BMYMP) invested $10.0B in research and development during fiscal year 2025.

How many shares does Bristol Myers have outstanding?

Bristol Myers (BMYMP) had 2.04B shares outstanding as of fiscal year 2025.

What is Bristol Myers's current ratio?

Bristol Myers (BMYMP) had a current ratio of 1.26 as of fiscal year 2025, which is considered adequate.

What is Bristol Myers's debt-to-equity ratio?

Bristol Myers (BMYMP) had a debt-to-equity ratio of 2.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bristol Myers's return on assets (ROA)?

Bristol Myers (BMYMP) had a return on assets of 7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bristol Myers's Piotroski F-Score?

Bristol Myers (BMYMP) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bristol Myers's earnings high quality?

Bristol Myers (BMYMP) has an earnings quality ratio of 2.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.